More Access and Evidence Articles

Access and Evidence

New EU Safety Symbol Identifies Pharmaceuticals Subject To Additional Monitoring

Lucy Brake, (Mar 11, 2013)

The European Commission has confirmed that the labels of medicinal products which are undergoing extra monitoring will be required to carry a new symbol to identify them.
Access and Evidence

Lawsuits against Generic Competition after Patent Increase for Pfizer’s Celebrex

Anonymous, (Mar 6, 2013)

Pfizer filed lawsuits against several US generic drug manufacturers after a patent for its drug Celebrex was reissued, thus extending its exclusivity to 18 months.
Access and Evidence

Compulsory Licence Upheld but Pricing Guidelines Waiting in the Wings

Louise Kelly, (Mar 6, 2013)

India’s Intellectual Property Appellate Board (IPAB) yesterday upheld the country’s first compulsory licence to a generic manufacturer for Bayer’s cancer drug Nexavar. The ruling sets a legal precedent for further patent challenges but new pricing guidelines may act as something of a safeguard.
Access and Evidence

India Considers Ending Compulsory Licensing Tactics

Ben Steele, (Feb 28, 2013)

Following a cold war between the Indian government and Big Pharma which has lasted for months, if not years, there are now indications that India may be looking to revise its compulsory licensing tactics.
Access and Evidence

Window dressing: Roche Launches New Process for Accessing Clinical Trial Data

Zuzanna Fimińska, (Feb 27, 2013)

Roche announced they will set up an 'independent body of recognized experts' to evaluate and approve requests to access patient-level clinical trial data by third party researchers.
Access and Evidence

NICE Backs All Trials Campaign

Zuzanna Fimińska, (Feb 26, 2013)

The UK National Institute for Health and Clinical Excellence (NICE) joined the supporters of the All Trials campaign, which calls on responsible bodies to ensure that all trials, past and present, for all treatments, are registered and that the full methods and full results are published.
Access and Evidence

The Challenging Pathway Ahead For Biosimilar Pharmaceuticals

Lucy Brake, (Feb 25, 2013)

Over the past couple of years there has been much debate about the development of biosimilars and the potential threat that these present for current innovator products.
Access and Evidence

An Increase in Drug Approvals – But at What Cost?

Ben Steele, (Feb 22, 2013)

The BMJ Open journal has reports that the number of new drugs introduced into the UK over the last thirty years has been rising, not falling. The bigger picture however, shows the rising costs of drug development and the steady decline of the R&D talent pool are still proving problematic.
Access and Evidence

Awarding Science Prodigies - Life Sciences Breakthrough Prize

Louise Kelly, (Feb 21, 2013)

A group of Silicon Valley moguls have launched an awards program that eclipses the Swedish Nobel Prize in terms of winnings. Over the next two years alone, $50m has been pledged to reward medical science innovation but will this scheme inspire new research or simply foster ‘old boy’ syndrome?
Access and Evidence

Real World Data: A Fundamental Tool

Louise Kelly, (Feb 21, 2013)

Louise Kelly speaks to Dr. John Parkinson, Director of the Clinical Practice Research Datalink about Real World Data, it's true value in improving the clinical development process and its ability to drive costs down.

Pages